5-hydroxymethylcytosine deposition mediates Polycomb Repressive Complex 2 function in MYCN -amplified neuroblastoma

Area of Science:

• Epigenetics
• Cancer Biology
• Developmental Biology

Background:

• MYCN amplification is a key driver of poor prognosis in neuroblastoma, a common pediatric cancer.
• Understanding the epigenetic landscape of MYCN-amplified neuroblastoma is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of 5-hydroxymethylcytosine (5-hmC) deposition in MYCN-amplified neuroblastoma.
• To explore the interplay between 5-hmC and Polycomb Repressive Complex 2 (PRC2) epigenetic marks.

Main Methods:

• Analysis of 5-hmC and H3K27me3 co-localization in neuroblastoma tumors.
• Investigating the functional consequences of inhibiting 5-hmC deposition.
• Assessing the impact of PRC2 inhibition on gene expression and drug sensitivity.

Main Results:

• MYCN-amplified neuroblastoma exhibits increased 5-hmC on PRC2 target genes, with direct co-localization of 5-hmC and H3K27me3 at the nucleosomal level.
• Genes marked by 5-hmC/H3K27me3 are involved in developmental pathways and are transcriptionally repressed.
• Inhibition of 5-hmC leads to H3K27me3 loss and sensitizes neuroblastoma to demethylating agents.
• 5-hmC primes H3K27me3-marked genes for activation upon PRC2 inhibition.

Conclusions:

• 5-hmC and H3K27me3 cooperate to repress developmental genes in MYCN-amplified neuroblastoma.
• This epigenetic interplay represents a novel mechanism linking DNA and chromatin modifications.
• Targeting this pathway holds potential therapeutic implications for neuroblastoma treatment.